Europeiska unionen - svenska - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Europeiska unionen - svenska - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunsuppressiva - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemi, myeloid - antineoplastiska medel - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

karolinska university hospital - fludeoxiglukos(f-18) - injektionsvätska, lösning - 450-11250 mbq/ml - fludeoxiglukos(f-18) 450 - 11250 mbq aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

novartis sverige ab - baklofen - injektions-/infusionsvätska, lösning - 0,5 mg/ml - baklofen 0,5 mg aktiv substans - baklofen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - baklofen - injektions-/infusionsvätska, lösning - 0,5 mg/ml - baklofen 0,5 mg aktiv substans - baklofen